Cullinan Therapeutics, Inc. CGEM

CGEM Company Overview

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a U.S.-based biopharmaceutical company focused on developing targeted therapies and immuno-oncology medicines for cancer and autoimmune diseases. The company operates within the biotechnology and precision medicine industries, emphasizing differentiated clinical-stage assets designed to address unmet medical needs. Cullinan’s strategy centers on advancing a portfolio of internally developed and partnered therapeutic candidates through clinical development while leveraging biomarker-driven patient selection and targeted mechanisms of action.

The company’s primary value drivers are its clinical-stage pipeline programs, including targeted oncology therapies and immune-modulating treatments. Key programs have included assets directed at EGFR-driven cancers, hematologic malignancies, and autoimmune indications. Cullinan was formed in 2016 under the name Cullinan Oncology and later expanded its scope beyond oncology, subsequently rebranding as Cullinan Therapeutics in 2024. The company has positioned itself as a focused development organization with a diversified pipeline structure intended to balance scientific innovation with capital efficiency.